Dr Lal PathLabs Q4 Revenue Up 16.6%

Dr Lal PathLabs reported Q4 FY26 revenue growth of 16.6% to ₹703 Cr with EBITDA margin of 26.6%.
PAT declined 15.1% YoY to ₹132 Cr due to one-time tax benefit reversal in prior year, but normalized PAT grew 15.1%.
Company declared final dividend of ₹4 per share and maintained strong cash position of ₹1,526 Cr as of March 31, 2026.
Full year FY26 revenue reached ₹2,763 Cr with 12.2% growth and normalized PAT growth of 17.9% to ₹532 Cr.